Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Canagliflozin on Insulin Sensitivity and Beta Cell Function in T2DM
NCT02009488Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2014
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Canagliflozin with Placebo (2 arms). Primary endpoints: Change from baseline in hepatic insulin sensitivity at 25 weeks, Change from baseline in peripheral tissue insulin sensitivity at 25 weeks and 3 more. Started Sep 2014; status: completed.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02009488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02009488.